GoodRx Holdings, Inc. (NASDAQ:
GDRX) is one of the
Best Penny Stocks to Buy with the Highest Upside Potential. Wall Street has a mixed opinion on GoodRx Holdings, Inc. (NASDAQ:GDRX) since the company released its fiscal second quarter results on August 6, 2025.
The company posted a revenue of $203.07 million, up slightly by 1.23% year-over-year, but below the consensus by $2.64 million. The EPS of $0.04 stayed in line with the expectations. Management noted that the prescription transaction revenue fell 3% to $143.1 million, mainly due to a 14% drop in Monthly Active Consumers caused by retail pharmacy changes. Moreover, the subscription revenue decreased 7% to $20.5 million, linked to fewer subscription plans.
Since the release, Wall Street has had a mixed opinion. For instance, on August 18, Michael Cherny from Leerink Partners reiterated a Buy rating on the stock with a price target of $6. Later on the same day, Steven Valiquette from Mizuho Securities reiterated a Hold rating on the stock with a price target of $5. More recently, on September 25, Allen Lutz from Bank of America Securities reiterated a Sell rating on $3.4 price target.
GoodRx Holdings, Inc. (NASDAQ:GDRX) is a US platform that helps consumers save money on medications.
While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at
Insider Monkey.
